pyrroles has been researched along with Sclerosis, Systemic in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (31.25) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Isomoto, H; Kimura, R; Sugihara, T; Sugita, K; Yamamoto, O | 1 |
| Fox, DA; Gudjonsson, JE; Huang, S; Kahlenberg, JM; Khanna, D; Khanna, PP; Lafyatis, R; Nagaraja, V; Padilla, C; Tabib, T; Tsoi, LC; Young, A | 1 |
| Andrade, CAS; Avelino, KYPS; Errachid, A; Oliveira, MDL; Pitta, MGR; Silva-Junior, AG | 1 |
| Ballerie, A; Batteux, F; Fardel, O; Jego, P; Jeljeli, M; Jouneau, S; Lecureur, V; Lelong, M; Lescoat, A; Morzadec, C; Piquet-Pellorce, C; Vernhet, L | 1 |
| Asano, Y; Fukushima, S; Hashizume, Y; Ide, M; Ihn, H; Jinnin, M; Kajihara, I; Tomizawa, Y; Wang, Z | 1 |
| Fujio, K; Hanata, N; Komai, T; Shoda, H | 1 |
| Deverapalli, SC; Rosmarin, D | 1 |
| Abraham, D; Baliga, R; Denton, CP; Derrett-Smith, EC; Dooley, A; Gilbane, AJ; Hobbs, AJ; Holmes, AM; Khan, K; Trinder, SL | 1 |
| Abou-Raya, A; Abou-Raya, S; Helmii, M | 1 |
| Kaburaki, J; Kuwana, M; Okazaki, Y | 1 |
| Anderson, M; Blann, A; Herrick, AL; Moore, TL; Murray, A; Sadik, HY; Vail, A | 1 |
| Alekperov, RT; Aleksandrova, EN; Anan'eva, LP; Korzeneva, EG; Novikov, AA | 1 |
| Batteux, F; Chéreau, C; Kavian, N; Marut, W; Nicco, C; Servettaz, A; Weill, B | 1 |
| Ihn, H; Jinnin, M; Tamaki, K | 1 |
| Ikeda, Y; Kaburaki, J; Kawakami, Y; Kuwana, M; Okazaki, Y; Yasuoka, H | 1 |
| Clancy, RM | 1 |
3 trial(s) available for pyrroles and Sclerosis, Systemic
| Article | Year |
|---|---|
Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.
Topics: Biomarkers; Endothelial Cells; Fibroblasts; Humans; Keratinocytes; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Scleroderma, Systemic; Treatment Outcome | 2022 |
Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Topics: Atorvastatin; Double-Blind Method; Female; Fingers; Health Status; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pain; Pain Measurement; Pyrroles; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Surveys and Questionnaires; Treatment Outcome | 2008 |
Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Scleroderma, Systemic; Time Factors; Vasodilation; Young Adult | 2010 |
13 other study(ies) available for pyrroles and Sclerosis, Systemic
| Article | Year |
|---|---|
Treatment of Digital Ulcers and Reflux Oesophagitis in a Patient with Systemic Sclerosis: Increased Risk of Hepatotoxicity due to a Potential Drug-drug Interaction Between Bosentan and Vonoprazan.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Drug Interactions; Esophagitis, Peptic; Humans; Pharmaceutical Preparations; Pyrroles; Scleroderma, Systemic; Sulfonamides; Ulcer | 2021 |
Nanoimmunosensor for the electrochemical detection of oncostatin M receptor and monoclonal autoantibodies in systemic sclerosis.
Topics: Autoantibodies; Biomarkers; Biosensing Techniques; Electrochemical Techniques; Gold; Humans; Immunoassay; Metal Nanoparticles; Polymers; Pyrroles; Receptors, Oncostatin M; Scleroderma, Systemic | 2023 |
Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Chemokine CXCL13; Female; Gene Expression Regulation; Hypochlorous Acid; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Lung; Lung Diseases, Interstitial; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Nitriles; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Receptors, Immunologic; Scleroderma, Systemic; Suppressor of Cytokine Signaling 3 Protein | 2020 |
Transforming growth factor β-inhibitor Repsox downregulates collagen expression of scleroderma dermal fibroblasts and prevents bleomycin-induced mice skin fibrosis.
Topics: Actins; Amino Acids; Aminopyridines; Animals; Bleomycin; Collagen Type I; Collagen Type I, alpha 1 Chain; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Humans; Inhibitory Concentration 50; Mice; Phenols; Pyrazoles; Pyridines; Pyrroles; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta; Up-Regulation; Xanthenes | 2017 |
Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis.
Topics: Arthritis; Female; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Scleroderma, Systemic | 2018 |
The use of JAK inhibitors in the treatment of progressive systemic sclerosis.
Topics: Adult; Humans; Janus Kinase Inhibitors; Male; Piperidines; Pyrimidines; Pyrroles; Scleroderma, Systemic | 2018 |
Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Endothelium, Vascular; Familial Primary Pulmonary Hypertension; Female; Hypertension, Pulmonary; Hypoxia; Indoles; Lac Operon; Male; Mice; Mice, Transgenic; Phenotype; Protein Serine-Threonine Kinases; Pulmonary Circulation; Pyrroles; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Signal Transduction; Transforming Growth Factor beta | 2013 |
Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cell Count; Cell Separation; Disease Progression; E-Selectin; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Flow Cytometry; Fluorescent Antibody Technique; Health Status; Heptanoic Acids; Humans; Immunoprecipitation; Middle Aged; Prospective Studies; Pyrroles; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Stem Cells; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
[Pleiotropic effects of statins in systemic sclerosis].
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cytokines; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Retrospective Studies; Scleroderma, Systemic; Treatment Outcome; Young Adult | 2011 |
Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Disease Progression; Fibroblasts; Indoles; Mice; Phosphorylation; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Skin; Sunitinib | 2012 |
Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression.
Topics: Cell Differentiation; Collagen Type I; Extracellular Matrix; Fibroblasts; Genes, Reporter; Humans; Isoquinolines; Luciferases; Phosphorylation; Promoter Regions, Genetic; Pyridines; Pyrroles; Scleroderma, Systemic; Signal Transduction; Skin; Smad3 Protein; Transfection; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation | 2006 |
Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis.
Topics: Adult; Aged; Atorvastatin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles; Scleroderma, Systemic | 2006 |
Preventing and repairing vascular damage in scleroderma: should we focus beyond vasodilatation to recruitment of endothelial precursor cells?
Topics: Arteries; Atorvastatin; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Scleroderma, Systemic; Vasodilation | 2006 |